








P Deshors¹, L Malric¹, F Arnauduc^{1,2}, A Lemarié^{1,3}, E Cohen-Jonathan-Moyal^{1,4,5}, C Toulas^{1,4}, M Courtade-Saïdi^{1,2,4}, S Evrard^{1,2,4}

1. INSERM U1037 CRCT, Toulouse, France - 2. Rangueil Faculty of Medicine, Toulouse, France - 3. Faculty of Pharmaceutical Sciences, Toulouse, France - 4. IUCT-ONCOPOLE, CHU Toulouse, France - 5. Purpan Faculty of Medicine, Toulouse, France



CONCLUSION
IONIZING RADIATIONS OF GSC POTENTIATES PROANGIOGENIC FEATURES OF TDEC VIA TIE2 SIGNALING PATHWAY
 Next step will be to test **pharmacological inhibitor of Tie2** like Regorafenib (indicated for patients with CRC, HCC or GIST) in vitro and in vivo on radio-induced transdifferentiation of GSC. Our ultimate goal is to identify a Tie2 inhibitor that can be used in clinic in order to **optimize efficiency of radiotherapy in GBM**.